



QUEEN'S
UNIVERSITY
BELFAST

DATA-CAN
The Health Data Research Hub for Cancer



I'm A Scholar Activist by Necessity

Prof Mark Lawler

Queen's University Belfast, UK;
DATA-CAN, the UK's Health Data Research Hub for Cancer
Cancer Drug Development Forum;
European Cancer Organisation;
European Cancer Patient Coalition;
Inspire2Live

Disclaimer

- ML has received honoraria from Bayer, Carnall Farrar, EMD Serono, Novartis , Pfizer, Roche unrelated to this work

This is the scale of the challenge we face in Europe!



This is the scale of the challenge we face in Europe!

But we also need to think about
the 20 million European citizens
who survive cancer

They need our support!



This is the scale of the challenge we face in Europe!

- Project to identify and address **cancer inequalities** in Europe
- Key to the success of the project was:
 - **Co-operation**
 - Cancer **Intelligence**¹
 - Patient **Involvement**
 - And then **more** Patient **involvement**
 - **Co-creation**
 - **Patience** and **perseverance**



The European Cancer Patient's Bill of Rights

- A **charter** to **challenge** the **inequalities** that cancer patients in Europe were **experiencing** on a **daily** basis¹
- A **catalyst for change** and an **empowerment tool** for cancer patients
- An **initiative** that has resonated across all of **Europe**



¹ Lawler et al *Lancet Oncology* 2014;

A vision for cancer control and cancer survival in Europe

- The 70:35 Vision - An average of 70% long-term survival for cancer patients in Europe by 2035, underpinned by research, with progress on cancer control, better survivor experience and improved quality of life
- How are we going to do it?
 - Working together and co-creation
 - Sharing Best Practice
 - Embedding Research and Innovation
 - Supporting Survivorship



Europe-wide recognition for a citizen focussed initiative

- **The European Cancer Patient's Bill of Rights** received the prestigious 2018 European Health Award
- Presented during the opening ceremony of the **European Health Forum Gastein** - The European Health Award recognises initiatives that have had Europe-wide impact



Keeping the focus on the patient: The European Code of Cancer Practice

- The **European Code of Cancer Practice** is a citizen and patient-centred manifesto of the **core requirements for good clinical cancer practice**, in order to improve outcomes for all of Europe's cancer patients.
- **Co-produced** by a team of cancer patients, patient advocates and cancer professionals.
- Launched on **23 September 2020** with **Commissioner Stella Kyriakides** and patients and health care professionals (HCPs) from across Europe
- Translated into **30 European Languages**
- **Significant Support** right across Europe

#cancerpatientrights #codeofcancerpractice europeancancer.org/code

European Code of Cancer Practice

YOU HAVE A RIGHT TO:



1. EQUAL ACCESS



2. INFORMATION



**3. QUALITY,
EXPERTISE &
OUTCOMES**



**4. SPECIALISED
MULTIDISCIPLINARY
CARE**



**5. SHARED
DECISION-MAKING**



**6. RESEARCH &
INNOVATION**



7. QUALITY OF LIFE



**8. INTEGRATED
SUPPORTIVE &
PALLIATIVE CARE**



**9. SURVIVORSHIP &
REHABILITATION**



10. REINTEGRATION



#cancerpatientrights #codeofcancerpractice

europeancancer.org/code

The Code in your language

- **Basque** – **Minbiziaren aurkako jarduteen Europar araudia**
Credit: Teodora Kolarova, International Neuroendocrine Cancer Alliance
- **Bulgarian** – **Европейски кодекс за онкологична практика**
Credit: Professor Eduard Vrdoljak Centre for Oncology, University of Split
- **Croatian** – **Europski kodeks za onkološke bolesti**
Credit: Anna Prokupkova, Association of European Cancer Leagues
- **Czech** – **Evropský kodex pro péči o rakovinu**
Credit: Jonas Van Riet, European Society of Radiology
- **Dutch** – **De Europese Code voor Kankerbestrijding**
Credit: Norbert Couespel, European Cancer Organisation; Ariane Weinman, EUC
- **English** – **European Code of Cancer Practice**
Credit: Professor Françoise Meunier, FEAM
- **Finnish** – **Eurooppalaiset syövänhoidon suosituks**
Credit: The Association of Cancer Patients in Finland
- **German** – **Der Europäische Kodex für die Krebspraxis**
Credit: Tamás Bereczky, EUPATI-DE / Patvocates
- **Greek** – **Ο Ευρωπαϊκός Κώδικας Πρακτικής του Καρκίνου**
Credit: Andreas Charalambous, European Oncology Nursing Society (EONS)
- **Hungarian** – **A Rákgyakorlat Európai Kódexe**
Credit: Csaba Dégi, International Psycho-Oncology Society
- **Italian** – **Codice Europeo di Prassi Contro il Cancro**
Credit: Giacomo Lazzaro, European Cancer Organisation
- **Lithuanian** – **Europos Vėžio Gydymo Kodeksas**
Credit: Šarunas Narbutas, Youth Cancer Europe
- **Latvian** – **Eiropas vēža prakses kodekss**
Credit: Agnese Abolina, European Cancer Organisation
- **Polish** – **Europejski Kodeks Postępowania Onkologicznego**
Credit: Prof Jacek Jassem, Department of Oncology and Radiotherapy, Medical University of Gdansk
- **Portuguese** – **Código Europeu de Práticas em Oncologia**
Credit: Associação de Investigação de Cuidados de Suporte em Oncologia
- **Romanian** – **Codul European De Practică A Cancerului**
Credit: Csaba Dégi, International Psycho-Oncology Society
- **Russian** – **Европейский Кодекс по Борьбе с Раковыми Заболеваниями**
Credit: Agnese Abolina, European Cancer Organisation; Olga Kozhaeva, SIOP Europe
- **Serbian** – **Europski kodeks za onkološke bolesti**
Credit: Marko Ocokoljić, SIOP Europe
- **Slovak** – **Európsky kódex starostlivosti o pacientov s rakovinou**
Credit: Darina Sedláková, League Against Cancer Slovakia
- **Slovene** – **Evropski kodeks prakse raka**
Credit: National Institute of Public Health, Slovenia
- **Spanish** – **El Código Europeo de Prácticas Contra el Cáncer**
Credit: Natacha Bolaños, Lymphoma Coalition; Alberto Crespo, European Cancer Organisation
- **Swedish** – **Europeiska kodexen för praxis inom cancervård**
Credit: Nathalie Nähr, MSc in Bioentrepreneurship
- **Turkish** – **Avrupa Kanser Uygulamaları Kodu**
Credit: Sema Erdem, Europa Donna
- **Welsh** – **Côd Ewropeaidd Gwasanaeth Cancr**

Why the European Code of Cancer Practice?

- To empower cancer patients to be **active participants** rather than **passive recipients** in their care
- To address the **inequalities** that many patients are experiencing every single day of their lives
- To ensure that patients receive quality treatment to achieve the best outcomes **no matter where they live**
- To achieve our aim of an average of **70% long term survival** for cancer patients by 2035 (**The 70/35 Vision**) with progress on cancer control, patient experience and quality of life
- To **embed rights that patients should expect** from their health system into European cancer policy

Empowering the Patient


- The **European Code of Cancer Practice** sets out a series of **10 key overarching rights**, and in particular **signposts what patients should expect** from their health system, in order for them to achieve the best possible outcomes.
- An **empowerment tool** to ensure the best available care is delivered for European citizens and patients.
- Each of the 10 overarching rights is **linked to three questions** that a patient/parent/guardian may choose to ask their healthcare professionals.

#cancerpatientrights #codeofcancerpractice

europeancancer.org/code

Tackling The East-West Equity Divide

- Our research revealed the significant inequalities that European citizens and patients are facing, particularly in Central and Eastern Europe (CEE)
- Critical Enablers for CEE countries:
 - **Robust** Cancer intelligence
 - **Resilient** National Cancer Control Plans (NCCPs)
 - **Patient-centred** multidisciplinary teams
 - A **research and innovation** empowered **culture**



European Code of Cancer Practice

YOU HAVE A RIGHT TO:



1. EQUAL ACCESS



2. INFORMATION



**3. QUALITY,
EXPERTISE &
OUTCOMES**



**4. SPECIALISED
MULTIDISCIPLINARY
CARE**



**5. SHARED
DECISION-MAKING**



**6. RESEARCH &
INNOVATION**



7. QUALITY OF LIFE



**8. INTEGRATED
SUPPORTIVE &
PALLIATIVE CARE**



**9. SURVIVORSHIP &
REHABILITATION**



10. REINTEGRATION


**european
cancer
ORGANISATION**

#cancerpatientrights #codeofcancerpractice

europeancancer.org/code

Critical Importance of Cancer Research to Cancer Care

- **Key message:** Cancer patients who are **treated in research-active hospitals have better outcomes than those who are not**
- **Embedding research within National Cancer Control Programmes is critical to our future health and wellbeing**
- **Cancer Mission** – an integral part of **Europe's Beating Cancer Plan**



Support at the Highest Level

04 February 2021, 16:45 - 18:45

Special Committee on Beating Cancer

Committees

BECA



Acquisition options:

“The European Cancer Organisation recently launched the European Code of Cancer Practice and I would be very happy to work together with the European Parliament that maybe we could combine this effort with the European Cancer Organisation.”

EU Health Commissioner Stella Kyriakides speaking to the European Parliament’s Special Committee on Cancer

04 February 2021



European Code of Cancer Practice

YOU HAVE A RIGHT TO:



1. EQUAL ACCESS



2. INFORMATION



**3. QUALITY,
EXPERTISE &
OUTCOMES**



**4. SPECIALISED
MULTIDISCIPLINARY
CARE**



**5. SHARED
DECISION-MAKING**



**6. RESEARCH &
INNOVATION**



7. QUALITY OF LIFE



**8. INTEGRATED
SUPPORTIVE &
PALLIATIVE CARE**



**9. SURVIVORSHIP &
REHABILITATION**



10. REINTEGRATION



#cancerpatientrights #codeofcancerpractice

europeancancer.org/code

We Need to Move the Dial...

- **Overarching attention** of European scientific/clinical communities to date has **focussed on cancer diagnosis and treatment**, rather than on living with and beyond cancer.
- BUT **20 million citizens** in Europe have **survived cancer**
- We must **greatly enhance** our engagement with cancer survivors and the **cancer survivorship agenda**, in order to ensure that the **specific survivorship challenges and needs** are **adequately addressed**



European Cancer
Patient Coalition



European Cancer
Patient Coalition

European Cancer Survivorship Research and Innovation Plan

- To address these challenges, we propose that a **European Cancer Survivorship Research and Innovation Plan** be embedded within the EU Cancer Mission¹
- This European Cancer Survivorship Research and Innovation Plan should have 3 distinct **Research Pillars**:
 - **The Medical Cancer Survivorship Research and Innovation Pillar**
 - **The Socio-Economic Cancer Survivorship Research and Innovation Pillar**
 - **The Politico-Legal Cancer Survivorship Research and Innovation Pillar**
- For each Pillar there are a series of **challenges** and **proposed solutions**

¹Lawler M, De Lorenzo F, Lagergren P, Mennini FS, Narbutas S, Scocca G, Meunier F; European Academy of Cancer Sciences. Challenges and solutions to embed cancer survivorship research and Innovation within the EU Cancer Mission *Mol Oncol* 2021

One of those Challenges is the Financial Discrimination that cancer survivors experience

- **You beat cancer** and yet.... **A new challenge arises**
- Problems getting a mortgage, loan, insurance, other financial challenges
- **The Right to Be Forgotten** ensures that cancer survivors can return to a productive life without facing financial discrimination



"We support the transposition of the Right to Be Forgotten legislation into Union-level legislation to prevent unfair discrimination in cancer patients' access to financial services and their reintegration into normal life." **Prof. Françoise Meunier**

<https://ecpc.org/policy/the-right-to-be-forgotten-a-new-research-project/>



European Cancer
Patient Coalition

The Right to be Forgotten

- A practical approach to ensure that **former cancer patients** can return to a normal **productive life without financial discrimination**
- Right **for a past illness no longer to be taken into account** for those patients living beyond cancer
- **10 years** after the end of treatment **for adults**
- **5 years for children** (either below 18 or 21 depending on the country)
- Earlier for cancers with excellent prognosis (e.g. breast, thyroid)
- Adopted in **France, Belgium, Luxembourg, the Netherlands, Portugal, and Romania**
- Much progress in **Cyprus, Ireland and Italy**

There is Life After Cancer

There is Life after Cancer:
Putting an End to the
Discrimination

- Twenty million reasons to get it right in Europe
- Please help us to stop this discrimination
- **CANCER PATIENTS SHOULD NOT HAVE TO PAY TWICE!**

Lawler M, Meunier F. Don't make cancer patients pay twice, the right to be forgotten should be the law everywhere *BMJ in press*



Deploying data and cancer intelligence for better care

- Recognising the **primacy of data**
- **Turning information into intelligence** is key
- The **patient** has a **critical role** to play in this **data-driven** revolution



Driving a “Big Data for Better Health” Agenda

Key issues of relevance for research and most importantly for patients:

- **Break down the silos:** Get academic researchers, clinicians, industry players, regulators and patients to collaborate and share data/code etc
- **Learn from the data:** Use data from diverse sources (‘omic, clinical, epidemiological, socio-economic etc) to increase our understanding of disease, mode of action of drugs, better drug targets etc
- **Big data for better health:** Use this intelligence to improve health and wellbeing of the citizen, enhance innovation and contribute to societal benefit

Championing a citizen-focussed Data Sharing Culture

- Facilitating **access** to **rich** data resources to **empower research and innovation**
- Establishing a **Cancer Data Knowledge Network**¹
- Moving from a Closed **“Selfish Silo”** Mentality to a more Open **“Collaborative Culture”**
- **Establish and maintain Public Trust** in the use of **“Big Data”**²

The NEW ENGLAND
JOURNAL of MEDICINE



25th May 2017

Sharing Clinical and Genomic Data on Cancer — The Need for Global Solutions

Mark Lawler, David Haussler, Lillian L. Siu, Melissa A. Haendel, Julie A. McMurry, Bartha M. Knoppers, Stephen J. Chanock, Fabien Calvo, Bin T. The, Guneet Walia, Ian Banks, Peter P. Yu, Louis M. Staudt, and Charles L. Sawyers, For the The Clinical Cancer Genome Task Team of the Global Alliance for Genomics and Health

¹Lawler et al *New Engl J Med* 2017

²Lawler et al *Lancet Oncology* 2018

A Question of Trust: Ensuring a citizen-focussed perspective

THE LANCET **Oncology**

- **Co-developing** a Citizen-focused **Data Sharing Cooperative with patients/citizens**
- Articulating a clear **Social Contract**, where citizens (as data donors) are at the heart of decision making.
- Embedding **ethical rigour** in all our data-driven processes
- **Democratising data analysis** for maximum scientific, clinical and patient value
- **Supporting** current data research environments and **enabling data “safe havens”(Trusted Research Environments(TRE))**
- *Embedding the Principle of The 5 Safes: “Safe people, working on safe projects, utilising safe data, in safe places, with safe outputs”*

Lawler et al *Lancet Oncology* 2018
A Roadmap for Restoring Trust in Big Data


Transforming the data landscape by Transcending disciplines

- We all need to **work together** to maximise the power of data

Patients
Clinicians
Pathologists
Geneticists
Cell/Molecular Biologists
Biochemists/Microbiologists/Immunologists
Biologists
Animal sciences
Bioinformaticians
Industry
Epidemiologists
Statisticians
Health service researchers
Astronomers
Geographers / Demographers
Social scientists
Environmental scientists
Economists
Lawyers
Ethicists
Theologians
Image analysts
Computer scientists
Mathematicians


Empowering a citizen-centred data-driven ecosystem

- A **cancer data ecosystem to drive research and innovation**
- Enabling **more effective** prevention and early diagnosis approaches
- Facilitating **application of data-enhanced discovery** to deliver innovative therapies
- **Nurturing and empowering** patient recovery and rehabilitation
- Underpinning **enhanced industry partnerships and innovation.**



Breaking down the data silos to create a “data translator” for enhanced cancer care


- [Variant Interpretation for Cancer Consortium \(VICC\)](#): A Driver Project of GA4GH
- Creation and application of the [VICC Meta-Knowledgebase](#), which aggregates all known information about gene mutations and variants of uncertain significance into a **single searchable resource for the cancer community**
- **Hundreds of siloed efforts** have sprung up around the globe to collate information about whether any particular variant is of concern. **But none of these knowledgebases spoke the same language.**
- Our **“data translator”** has harmonised the information and made it freely available online to the entire cancer community



Wagner AH, Walsh B, Mayfield G, ..., Lawler M, Goecks J, Griffith M, Griffith OL, Margolin AA; Variant Interpretation for Cancer
[A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer.](#) *Nat Genet.* 2020


DATA-CAN: The vision

- **Improve access to existing data**
 - Clinical, academic and commercial
- **Improve quality of data**
 - Better data at the point of care
 - Enhanced curation of current data
- **Improve UK coverage**
 - Four nations of the UK
- **Add new datasets at scale**
 - Genetic/molecular, imaging, pathology
 - Primary care, Patient Related Outcome Measures (PROMs)
- **Ensure fair value**
 - Patients, Clinicians/NHS, Researchers, Industry



Patients are at the heart of what we do

- Patients are involved **at all levels of decision- making**
- Integrate **patient/public led** research ideas and projects
- **Enable genuine co-creation** of research
- Involve patients in discussions **with all research partners, including commercial partners**
- **Empower underserved and minority communities** whose voice is often unheard



Jacqui Gath, Cancer survivor. patient advocate

"As patients we not only are empowered but we feel empowered"

And Then the World Changed....

For Me Covid-19 was personal



[Eur J Cancer](#). 2020 Jun; 132: 98–99.

Published online 2020 Apr 18. doi: [10.1016/j.ejca.2020.04.001](https://doi.org/10.1016/j.ejca.2020.04.001)



PMCID: PMC7165280

PMID: [32335477](https://pubmed.ncbi.nlm.nih.gov/32335477/)

Cancer and coronavirus disease 2019; how do we manage cancer optimally through a public health crisis?

[Eduard Vrdoljak](#),^{a,*} [Richard Sullivan](#),^b and [Mark Lawler](#)^c

“People are starting to fear a Covid-19 diagnosis more than a cancer diagnosis”



- **BUT WHERE WAS THE EVIDENCE?**
- **Data-Driven Collaboration** between DATA-CAN and UCL
- **Accessing Real Time Data** from Hospital Trusts across the UK
- **Modelling excess deaths** due to the adverse effects of the Covid pandemic

Covid-19 and Cancer: “Real Time” Data analysis


- We accessed / analysed data from Hospital Trusts across the UK
- **7 out of 10 people with suspicion of cancer were either not going to their GP or not getting referred to cancer specialist services**
- **4 out of 10 cancer patients were not getting access to their chemotherapy**
- **First data that drew attention of the government, academia, NHS and the public to the disastrous impact of Covid-19 on cancer services and cancer patients**

Impact on cancer services has been catastrophic

EXCLUSIVE



- By [Tom Bawden](#) 18th March 2021
- A new analysis finds a huge backlog of endoscopy procedures that are crucial for
- a number of gastrointestinal cancers




- April 2020: **10,476** endoscopies
- April 2019: **110,584** endoscopies
- **UK could have thousands of extra cancer deaths due to COVID delaying 500,000 endoscopies**

Ho KMA, Banerjee A, Lawler M, Rutter MD, Lovat LB. [Lancet Gastroenterol Hepatol.](#) 2021

Disruptions to cancer services across the cancer pathway due to the Covid-19 pandemic

- Disruption was felt across the **entire cancer pathway**
- **Presentational / Diagnostic** Delay; significant **impact on treatment**
- **Significant disruption of cancer research** (clinical trials, discovery research, translational research)



Sud A, Torr B, Loveday C, Jones M, Broggio J, McFerran E, Lawler M, Houlston R, Turnbull C.


Lancet Oncology 2020

<https://www.carnalfarrar.com/life-sciences/life-sciences-insights/disruption-and-recovery-of-cancer-from-covid-19/>

Covid-19 and Cancer: Excess Mortality

B

- Looked at **excess mortality** on data from nearly 4M citizens
- **Modelled different scenarios** to determine excess deaths due to pandemic
- **Used Real Time Data** from Hospital Trusts **to Inform the Model**
- **Predicted 7,165 – 17,910 excess deaths**




Lai AG, Pasea L, Banerjee A,Sullivan R, Davie C, Lawler M, Hemingway H *BMJ Open*. 2020;

One Step Forwards, Two Steps Backwards

- Assuming **3 months of disruption** (which is conservative), **stage shift** in detection of cancer (i.e. detecting cancer later rather than earlier) due to disruptions to the cancer pathway **could significantly affect five-year survival**
- For certain cancers e.g. colorectal, the **Covid-19 pandemic could set us back nearly a decade**

Five-year survival anticipated for 2020 (England)



SOURCE: CF analysis, Office for National Statistics, Cancer survival in England, adults diagnosed
* Anticipated 5-year survival for 2020, calculated from 2017 figures

DATA is also helping us to support the recovery

- Presentational/diagnostic/treatment delays in colorectal cancer due to Covid-19 have potential to cause significant excess deaths and loss of life years
- Our work¹ shows that prioritisation using Faecal Immunochemical Testing (FIT) can help avoid nearly 90% of these excess deaths, whilst reducing immediate requirement for colonoscopy by >80%.
- Can support both the health system (by prioritising use of tests (e.g. colonoscopy) for those who most require them, thereby solving capacity problems), but more importantly patients – to ensure that presentational/diagnostic delays are reduced

¹Loveday C, Sud A, Jones M, Broggio J, McFerran E, Muller DC, Abulafi M, Lawler M, Houlston R, Turnbull C. Gut 2020

Covid-19 (like Cancer) does not respect Borders



- Presented our data to the **European Cancer Organisation (E.C.O)** (Europe's largest multidisciplinary cancer organisation) and to WHO Europe
- In light of the dramatic impact of Covid, the Board of E.C.O. decided to launch a **Special Network on the Impact of Covid-19 on Cancer**, co-chaired by Board members Mirjam Crul and Mark Lawler.
- Rapidly convened a panel of experts from across Europe
- Led to development of a **7-Point Plan to mitigate the impact of Covid**




<https://www.europecancer.org/topic-networks/16:impact-of-covid-19-on-cancer>

Our 7-Point Plan to Build Back Better (And Smarter)


1. Urgently addresses the **cancer backlog**
2. **Restores confidence** of European citizens and patients in cancer health services
3. **Tackles** medicines, products and equipment **shortages**
4. **Addresses cancer workforce gaps** across Europe
5. Employs innovative technologies to **strengthen cancer systems** and provide optimal care to cancer patients
6. Embeds data collection and the **rapid deployment of cancer intelligence** enhance policy delivery
7. Secures deeper **pan-European health cooperation**

Cancer must not become the Forgotten “C” in the Fight against Covid-19.



Cancer must be at the top of the Recovery Agenda

- "Time To Act" Campaign
- Underpinned the Time To Act campaign with **evidence-based intelligence**
- Data Intelligence study presented to the **Europe Beating Cancer Committee** (10th May 2021)
- **We demand that cancer must be put at the top of the European Health Agenda**



Lawler M, Crul M. Data must underpin our response to the covid-19 pandemic's disastrous impact on cancer. *BMJ*. 2022

Data Intelligence: Impact on cancer screening and diagnosis



Impact of Covid-19 on Cancer patients seen

Clinicians across Europe saw **1.5 million fewer Cancer patients** in the first year of the pandemic



Impact of Covid-19 on Cancer screening

100 million Cancer screening tests were **not performed** in Europe as a result of the pandemic



Impact of Covid-19 on Cancer diagnosis

1 million Cancer patients could be undiagnosed due to the presentational/diagnostic backlog

Data Intelligence: Impact on cancer patients/cancer professionals



Impact of Covid-19 on Cancer treatment

During the pandemic, **1 in 2 Cancer patients** in Europe **did not receive the surgical or chemotherapy treatment** they needed on time, and **1 in 5**, their treatment is still being delayed



Impact of Covid-19 on Cancer patients

Due to fears of contracting Covid-19, **citizens and patients** are **less likely to attend screening appointments** or **go to hospital for cancer treatment**



Impact of Covid-19 on Cancer workforce

The pandemic has taken its toll on healthcare workers with **4 in 10 feeling burnout** and **3 in 10 showing signs of clinical depression**

Patient Centred Initiative with pan-European relevance

- **Official European virtual launch** 11th May 2021
- **Poland:** 22 May 2021
- **Italy:** 17th June 2021
- **Spain:** 25th June 2021*
- **Romania:** 9th September 2021
- **Malta:** 14th September 2021
- **France:** 22nd September 2021
- **Croatia:** 12th October 2021
- **Cyprus:** 14th October 2021
- **Slovenia:** 22nd October 2021
- **Portugal:** 27nd October 2021
- **Slovakia:** 21st January 2021
- **Ireland:** 4th February 2022



***Premio Extraordinario a la Mejor
Iniciativa Científica Europea en
Award**




TIME TO ACT: Cancer won't wait – Neither Should We!



- Data intelligence informed Campaign messages for public, patients, health professionals and policy-makers (translated into **30 European languages**)

Cancer Patients and Citizens:

- **Don't Delay:** See your Doctor if you have **Warning Signs of Cancer**. Keep your Screening and Treatment appointments.
- **Cancer services are safe.**




Policy-makers and Health System Leaders:

- Getting **cancer** services back on **track must be top of the agenda**. Every action now to **address the cancer backlog will help save lives.**



Time To Act Data Navigator

- A new landmark tool in the fight against the impact of Covid-19 on cancer,
- Initial data from 17 European countries
- Website – timetoactcancer.com/data-navigator
- Captures data intelligence on
 - Country cancer profile
 - Covid-19 impact on **cancer screening**
 - Covid-19 impact on **cancer diagnosis**
 - Covid-19 impact on **cancer treatment**
 - Covid-19 impact on **patients and people at risk**
 - Covid-19 impact on **healthcare professionals**



'Time To Act' won European *Communiqué* Award

- Our entry *Time to Act: Informing policy action to tackle the impact of Covid-19 on cancer care across Europe* won **the Communiqué Awards 2022**



- ✓ Category of Excellence in Communicating and Using Data


- Communiqué recognises, rewards, and commends excellence and best practice in healthcare communications in Europe
- Best initiative **in Europe** in this category

Covid and Cancer work also received the 2021 Royal College of Physicians Excellence in Patient Care award



Time To Act Data Navigator: A Tool Supporting Policy Decision-making

- Recognition at the EU level –
- President of the European Commission **Ursula von der Leyen** referenced the Time To Act Data intelligence – **One million undiagnosed cases**
- **Stella Kyriakides** referred to the Time To Act Data Intelligence – **An estimated one million cancer cases could be undiagnosed in Europe**




timetoactcancer.com/data-navigator

Data Navigator Expansion

Updated Data Navigator: October 2022

- **New section with cancer tumour type data** for:
 - ✓ Lung Cancer
 - ✓ Breast Cancer
 - ✓ Colorectal Cancer
 - ✓ Prostate Cancer
- **New data and updates** for all WHO European Region countries, where available
 - ✓ Over 70 new studies identified and analysed



timetoactcancer.com/data-navigator



Special Network on COVID and Cancer What's Next?

- A comprehensive update of the **COVID-19 and Cancer Data Navigator** to highlight trends and particular tumour impacts
- Engagement with the **European Parliament's Special Committee on COVID-19** to ensure a **strong cancer focus** in its hearings and recommendations
- Associated to this, the Network will:
 - Publish a 2022 update to its 2020 **'7 point plan' to Build Back Better (and Smarter)**
 - Conduct a call for **case studies in COVID-19 Build Back** to support our revised 7 Point Plan



Time To Act at UICC World Cancer Congress

- **A virtual session dedicated to Time To Act** is included in the programme of the UICC World Cancer Congress
- The format will be a 40 minutes on-demand video including **short presentations**, conversations with **high-level speakers** and **animated infographics**
- **The recording will be available on the UICC virtual platform from 18 October until 31 December 2022** with opportunities for networking and interactions with speakers and guests.





european
cancer

**16 & 17
NOVEMBER**

**Time To Act session at the
European Cancer Summit 2022:**

Thursday 17 November
10:30-11:45 CEST

More information will be
available soon on
europeancancer.org/summit

**european cancer
SUMMIT 2022**

**Delivering Effective
and Equitable
Care Together**

#europeancancersummit



- Don't let Covid-19 stop you from tackling Cancer.
- TimeToActCancer.com
- #TimeToActCancer

Tear Down The Silos!



Unlocking the Power of Data to improve our health and wellbeing

